ResMed Shares Slip Amid Eli Lilly's FDA Approval
ResMed shares decline after FDA approves Eli Lilly's weight-loss treatment for sleep apnea, impacting the sleep therapy market.
Topic
RMD
A collection of 3 issues
ResMed Shares Fall 4% After FDA Approves Eli Lilly's Zepbound
ResMed stock drops 4% as Eli Lilly's Zepbound receives FDA approval for sleep apnea, impacting the competitive landscape.
ResMed Shares Slide on FDA Approval of Eli Lilly's Zepbound
ResMed's stock dips 4% following FDA approval of Eli Lilly's Zepbound, increasing competition in the sleep apnea treatment market.